Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. develops novel biologic antibody programs for inflammatory and immunology diseases, with disclosed focus areas including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its programs target established mechanisms of action and use antibody engineering intended to optimize half-life and dosing properties.
Recurring APGE news includes clinical data and pipeline updates for zumilokibart (APG777), APG279, which combines zumilokibart with APG990, and APG333. Company updates also cover operating and financial results, public equity offerings, management conference participation, shareholder-voting matters, governance changes and financing activity to support preclinical studies, clinical trials, manufacturing, commercial readiness and general corporate purposes.
Apogee Therapeutics (Nasdaq: APGE) announced management participation in two June 2026 investor conferences.
The company will join the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026 at 9:20 a.m. ET. Live and archived webcasts will be accessible on Apogee's investor website.
Apogee Therapeutics (Nasdaq: APGE) entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital to advance Phase 3 development and potential commercialization of zumilokibart.
The deal includes up to $800 million in synthetic royalty funding and access to up to $500 million in senior corporate debt. Combined with Apogee’s $1.3 billion in cash, the company believes this supports a self-sustainable financial profile through commercialization without future equity financing.
Apogee Therapeutics (Nasdaq: APGE) reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis.
The trial met all primary and secondary endpoints; 65.9% of mid-dose patients achieved EASI-75 vs 23.4% placebo. Mid-dose will advance to planned Phase 3 in 2H 2026. Safety was generally consistent with class. A new financing collaboration with Blackstone Life Sciences is expected to fund development through potential commercialization in AD, asthma and EoE.
Apogee Therapeutics (Nasdaq: APGE) will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis on May 27, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET, with a replay available afterward via its investor website.
Apogee Therapeutics (Nasdaq: APGE) reported Q1 2026 results and major pipeline progress. Cash, cash equivalents and securities rose to $1.3 billion, aided by a $403 million upsized equity offering, extending runway into 2029.
Phase 2 APEX 52-week data for zumilokibart in atopic dermatitis showed durable maintenance and improved efficacy with every 3- and 6-month dosing, supporting planned Phase 3 initiation in 2H 2026 and a future BLA filing in AD.
Apogee Therapeutics (Nasdaq: APGE) closed an underwritten public offering of 5,750,000 common shares at $70.00 per share, including full exercise of the underwriters’ option for 750,000 additional shares, generating approximately $403 million in gross proceeds before fees.
The offering used an effective shelf registration filed August 12, 2024, and was led by Jefferies, TD Cowen, Stifel and Guggenheim.
Apogee Therapeutics (Nasdaq: APGE) priced an underwritten public offering of 5,000,000 common shares at $70.00 per share, for aggregate gross proceeds of approximately $350 million.
The offering is expected to close on March 26, 2026, subject to customary closing conditions, and underwriters have a 30-day option to purchase up to an additional 750,000 shares.
Apogee Therapeutics (Nasdaq: APGE) announced a proposed underwritten public offering of $300 million of common stock on March 23, 2026, with a 30‑day option for underwriters to purchase up to an additional $45 million.
Net proceeds are intended to fund preclinical and clinical programs, manufacturing, commercial readiness, R&D, capital expenditures, working capital and general corporate purposes. The offering is subject to market conditions and will be made by prospectus supplement under an existing registration statement.
Apogee Therapeutics (Nasdaq: APGE) reported positive 52-week Phase 2 Part A results for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. The study showed durable maintenance and deepening of responses with both 3-month and 6-month maintenance dosing, and a safety profile consistent with the class.
Key metrics: EASI-75 maintenance of 75% (3-month) and 85% (6-month) and vIGA 0/1 maintenance of 86% (3-month) and 78% (6-month) among Week 16 responders. Part B 16-week induction data expected 2Q 2026; Phase 3 initiation planned for 2H 2026, with potential launch in 2029, subject to outcomes.
Apogee Therapeutics (NASDAQ: APGE) will report Part A 52-week results from the Phase 2 APEX trial of zumilokibart (APG777) on Monday, March 23, 2026. Following the announcement, the company will host a conference call and live webcast at 8:00 a.m. ET.
According to the company, the live webcast will be accessible via the Investors section on the company website and a replay will be available after the call.